Frontotemporal dementia
https://doi.org/2618-6667-2018-77-60-85
Abstract
The aim of work was to present the analysis of current scientifc publications devoted to the problem of frontotemporal dementia. Material and methods: according to the key words «frontotemporal dementia» and «frontotemporal lobar degeneration» publications over the last two decades were chosen and analyzed in PubMed, MEDLINE, and other scientifc bases. Results: at present the phenomenology and diagnostic criteria of the basic types of frontotemporal dementia (FTD) are presented in the literature in the most developed form. The progress in recognition of the disease and its separate types is based on the results of investigation of modern neuroimaging methods diagnostic signifcance. FTD is considered to be one of the leading reasons for early onset of dementia, however, the prevalence of FTD in the population of senior age groups has been studied insufciently. Achievements of molecular-genetic FTD studies determine directions of further research of the pathogeny of the disease and perfection of its systematics. Prospectivity of investigation of separate risk factors and their combinations as an important task of further clinical and population studies was substantiated. The results of symptomatic therapy with application of memantin for the treatment of dementia as well as SSRI for correction of behavioral disorders were considered. Conclusion: the perfection of FTD systematics and the achievements of neurosciences create the prospects of the development of effective methods of symptomatic pharmacotherapy (memantin, SSRI) and nosomodifcating therapeutic intervention with application of gene technologies.
About the Author
Yana Fedorova
FSBSI «Mental Health Research Centre», Moscow
Russian Federation
PhD, MD, candidate of medical sciences, senior researcher
Russian Federation
PhD, MD, candidate of medical sciences, senior researcher
References
1. Pick A. Über die beziehungen der senilen hirnatrophie zur aphasie. Prager Medicinische Wochenschrift. 1892;17:165–167.
2. Alzheimer A. Uber eigenartige Krankheitsfalle des spateren Alters. Z. NeuraI. 1911;4:356–385.
3. Richter H. Eine besondere Art von Stirnhirnschwund mit Verblödung. Z. Neurol. 1918;38:127–159.
4. Gans A. Betrachtungen über art und ausbreitung des krankhaften prozesses in einem fall von Pickscher atrophie des stirnhirns. Z. ges Neurol. Psychiat. 1923;80:10–28.
5. Van Mansvelt J. Piek’s disease. A syndrome of lobar cerebral atrophy, its clinico-anatomical and histopathologieal types. Thesis University Utrecht, 1954.
6. Constantinidis J., Richard J., Tissot R. Pick’s disease: histological and clinical correlations. Eur. Neurol. 1974;11:208–217.
7. Mesulam M.M. Slowly progressive aphasia without generalized dementia. Ann. Neurol. 1982;11:592–598.
8. Morris J.C., Cole M., Banker B.Q., Wright D. Hereditary dysphasic dementia and the Pick-Alzheimer spectrum. Ann. Neurol.1984. Oct;16(4):455–466. doi: 10.1002/ana.410160407
9. Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch. Gerontol. Geriatr. 1987;6:193–208.
10. Neary D., Snowden J.S., Northen B., Goulding P. Dementia of frontal lobe type. J. Neurol. Neurosurg. Psychiatry. 1988;51:353–361.
11. Miller B.L., Cummings J.L., Villanueva-Meyer J., Boone K., Mehringer C.M., Lesser I.M., Mena I. Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology. 1991 Sep;41(9):1374–1382.
12. Lund and Manchester Groups Clinical and neuropathological criteria for frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 1994;57:16–418.
13. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology.1998; Dec;51(6):1546–1554.
14. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., Hillis A., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K., Johnson J.K., Tempini M.-L.G., Rosen H., Neuhaus J., Latham C., Lee A.S., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Le- bert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Warren J.D., Fox N.C., Grossman M., Miller B.L. Sensitivity of diagnostic criteria in autopsy-confirmed patients with behavioral variant Frontotemporal Dementia (bvFTD): First Report of the International bvFTD Criteria Consortium (FTDC). Neurology. 2011;76:A262–263.
15. Knopman D.S., Boeve B.F., Parisi J.E., Dickson D.W., Smith G.E., Ivnik R.J., Josephs K.A., Petersen R.C. Antemortem diagnosis of frontotemporal lobar degeneration. Ann. neurol. 2005;57:480–488. doi: 10.1002/ana.20425
16. Mendez M.F., Shapira J.S., McMurtray A., Licht E., Miller B.L. Accuracy of the clinical evaluation for frontotemporal dementia. Arch. Neurol. 2007;64:830–835. doi: 10.1001/archneur.64.6.830
17. Piguet O., Hornberger M., Shelley B.P., Kipps C.M., Hodges J.R. Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia. Neurology. 2009;72:732–737. doi: 10.1212/01.wnl.0000343004.98599.45
18. Pijnenburg Y.A., Mulder J.L., van Swieten J.C., Uitdehaag B.M., Stevens M., Scheltens P., Jonker C. Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population. Dement. Geriatr. Cogn. Disord. 2008;25:157–64. doi: 10.1159/000112852
19. Snowden J.S., Thompson J.C., Stopford C.L., Richardson A.M., Gerhard A., Neary D., Mann D.M. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain. 2011;134:2478–2492. doi: 10.1093/brain/awr189
20. Yolande A.L. Pijnenburg. New diagnostic criteria for the behavioural variant dementia. European Neurological Review. Touch Briffing. 2011:234–237. doi: http://doi.org/10.17925/ENR.2011.06.04.234
21. Román G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., Moody D.M., O’Brien M.D., Yamaguchi T., Grafman J., Drayer B. P., Bennett D.A., Fisher M., Ogata J., Kokmen E., Bermejo F. & 11 others. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260.
22. McKeith I.G., Dickson D.W., Lowe J., Emre M., O’Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Ga- lasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65:1863–1872. doi: 10.1212/01.wnl.0000187889.17253.b1
23. McKhann G. M., Knopman D. S., Chertkow H., Hyman B.T., Jack C.R. Jr., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of de- mentia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005
24. Johnson J.K., Diehl J., Mendez M.F., Neuhaus J., Shapira J.S., Forman M., Chute D.J., Roberson E.D., Pace-Savitsky C., Neumann M., Chow T.W., Rosen H.J., Forstl H., Kurz A,, Miller B.L. Frontotemporal lobar degeneration; demographic characteristics of 353 patients. Arch. Neurol. 2005;62:925–930. doi: 10.1001/archneur.62.6.925
25. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A,E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J,K., Gorno-Tempini M.L., Ros- en H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnen- burg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477. doi: 10.1093/brain/awr179
26. Garcin B., Lillo P., Hornberger M., Piguet O., Dawson K., Nestor P.J., Hodges J.R. Determinants of survival in behavioral variant frontotemporal dementia. Neurology. 2009;73:1656–1661. doi: 10.1212/ WNL.0b013e3181c1dee7
27. Rascovsky К., Grossman М. Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration. Int. Rev. Psychiatry. 2013;25:145–158. doi: 10.3109/09540261.2013.763341
28. Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Gorno-Tempini M.L. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch. Neurol. 2008;65:249–255. doi: 10.1001/archneurol.2007.38
29. Rosen H.J., Gorno-Tempini M.L., Goldman W.P. et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology. 2002;58:198–208.
30. Boccardi M., Sabattoli F., Laakso M.P., Testa C., Rossi R., Beltramello A., Soininen H., Frisoni G.B. Frontotemporal dementia as a neural system disease. Neurobiol. Aging. 2005;26:37–44. doi: 10.1016/ j.neurobiolaging.2004.02.019
31. Schroeter M.L., Raczka K., Neumann J., von Cramon D.Y. Neural networks in frontotemporal dementia: a meta-analysis. Neurobiol. Aging. 2008;29:418–426. doi: 10.1016/j.neurobiolaging.2006.10.023
32. Rabinovici G.D., Seeley W.W., Kim E.J., Gorno-Tempini M.L., Rascovsky K., Pagliaro T.A., Allison S.C., Halabi C., Kramer J.H., Johnson J.K., Weiner M.W., Forman M.S., Trojanowski J.Q., Dearmond S.J., Miller B.L., Rosen H.J. Distinct MRI atrophy patterns in autopsy-proven Alzheimer’s disease and frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen. 2007;22:474–488. doi: 10.1177/1533317507308779
33. Rosen H.J., Allison S.C., Schauer G.F., Gorno-Tempini M.L., Weiner M.W., Miller B.L. Neuroanatomical correlates of behavioural disorders in dementia. Brain. 2005;128:2612–2625.doi: 10.1093/ brain/awh628
34. Woolley J.D., Khan B.K., Murthy N.K., Miller B.L., Rankin K.P. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease; rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. Clin. Psychiatry. 2011;72:126–133. doi: 10.4088/JCP.10m06382oli
35. Hodges J.R., Patterson K., Oxbury S., Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115:1783–1806.
36. Snowden J.S., Neary D., Mann D.M., Goulding P.J., Testa H.J. Pro- gressive language disorder due to lobar atrophy. Ann. Neurol. 1992;31:174–183.
37. Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M. Classification of primary progressive aphasia and its variants. Neu- rology. 2011;76:1006–1014. doi: 10.1212/WNL.0b013e31821103e6
38. Ikeda M., Patterson K., Graham K.S., Ralph M.A., Hodges J.R. A horse different colour: Do patient with semantic dementia recognize different versions of the object as the same? Neuropsychologia. 2006; 44:566–575. doi: 10.1016/j.neuropsychologia.2005.07.006
39. Brambati S.M., Ogar J., Neuhaus J., Miller B.L., Corno-Tempini M.L. Reading disorders in primary progressive aphasia: a behavioral and neuroimaging study. Neuropsychologia. 2009;47(8–9):1893–1900. doi: 10.1016/j.neuropsychologia.2009.02.033
40. Meteyard L., Patterson K. The relation between content and structure in language production: an analysis of speech errors in semantic dementia. Brain Lang. 2009;110(3):121–134. doi: 10.1016/j.bandl.2009.03.007
41. Wilson S.M., Henry M.L., Besbris M., Ogar J.M., Dronkers N.F., Jarrold W., Miller B.L., Gorno-Tempini M.L. Connected speech production in three variants of primary progressive aphasia. Brain. 2010;133(Pt 7):2069–2088. doi: 10.1093/brain/awq129
42. Mesulam M.M., Wieneke C., Hurley R., Rademaker A., Thompson C.K., Weintraub S., Rogalski E.J. Words and objects at the tip of the left temporal lobe in primary progressive aphasia. Brain. 2013;139(Pt 2):601–618. doi: 10.1093/brain/aws336
43. Gainotti G. Why are the right and left hemisphere conceptual representations different? Behav. Neurol. 2014;2014:603134. doi: 10.1155/2014/603134
44. Wilson S.M., Brambati S.M., Henry R.G., Handwerker D.A., Agosta F., Miller B.L., Wilkins D.P., Ogar J.M., Gorno-Tempini M.L. The neural basis of surface dyslexia in semantic dementia. Brain. 2009;132(Pt l):71–86. doi: 10.1093/brain/awn300
45. Gorno-Tempini M.L., Murray R.C., Rankin K.P., Weiner M.W., Miller B.L. Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase. 2004;10(6):426–436. doi: 10.1080/13554790490894011
46. Agosta F., Henry R.G., Migliaccio R., Neuhaus J., Miller B.L., Dronkers N.F., Brambati S.M., Filippi M., Ogar J.M., Wilson S.M., Gorno-Tempini M.L. Language networks in semantic dementia. Brain. 2010;133(Pt l):286–299. doi: 10.1093/brain/awp233
47. Mummery C.J., Patterson K., Price C.J., Ashburner J., Frackowiak R.S.J., Hodges J.R. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic dementia. Ann. Neurol. 2000;47:36–45.
48. Galton C.J., Patterson K., Graham K., Lambon-Ralph M.A., Williams G., Antoun N., Sahakian B.J., Hodges J.R. Differing patterns of temporal atrophy in Alzheimer’s disease and semantic dementia. Neurology. 2001;57(2):216–225.
49. Chan D., Fox N.C., Scahill R.I., Crum W.R., Whitwell J.L., Leschziner G., Rossor A.M,, Stevens J.M., Cipolotti L., Rossor M.N. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer’s disease. Ann. Neurol. 2001;49(4):433–442.
50. Rosen H.J., Allison S.C., Ogar J.M., Amici S., Rose K., Dronkers N., Miller B.L., Gorno-Tempini M.L. Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology. 2006;67(10):1752–1756. doi: 10.1212/01.wnl.0000247630.29222.34
51. Diehl J., Grimmer T., Drzezga A., Riemenschneider M., Forstl H., Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol. Aging. 2004;25(8):1051–1056. doi: 10.1016/j.neurobiolaging.2003.10.007
52. Galantucci S., Tartaglia M.C., Wilson S.M., Henry M.L., Filippi M., Agosta F., Dronkers N.F., Henry R.G., Ogar J.M., Miller B.L., Gorno-Tempini M.L. White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain. 2011;134(Pt 10):3011–3029. doi: 10.1093/brain/awr099
53. Whitwell J.L., Avula R., Senjem M.L., Kantarci K,, Weigand S.D., Samikoglu A,, Edmonson H.A., Vemuri P., Knopman D.S., Boeve B.F., Petersen R.C., Josephs K.A., Jack C.R. Jr. Gray and white matter water diffusion in the syndromic variants of frontotemporal demen tia. Neurology. 2010;74(16):1279–1287. doi: 10.1212/WNL.0b013e-3181d9edde
54. Josephs K.A., Whitwell J.L., Knopman D.S., Boeve B.F., Vemuri P., Senjem M.L., Parisi J.E., Ivnik R.J., Dickson D.W., Petersen R.C., Jack C.R. Jr. Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology. 2009;73(18):1443–1450. doi: 10.1212/WNL.0b013e3181bf9945
55. Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111–113. doi: 10.1007/s00401-011-0845-8
56. Hodges J.R., Mitchell J., Dawson K., Spillantini M.G., Xuereb J.H., McMonagle P., Nestor P.J., Patterson K. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133(Pt l):300–306. doi: 10.1093/brain/awp248
57. Knibb J.A., Xuereb J.H., Patterson K., Hodges J.R. Clinical and pathological characterization of progressive aphasia. Ann. Neurol. 2006;59:156–165. doi: 10.1002/ana.20700
58. Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M, Phengrasamy L., Rosen H.J., Johnson J.K., Weiner M.W., Miller B.L. Cognition and anatomy in three variants of primary progressive aphasia. Ann. Neurol. 2004;55:335–346. doi: 10.1002/ana.10825
59. Rogalski E., Cobia D., Harrison T.M., Wieneke C., Weintraub S., Mesulam M.M. Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia. Neurology. 2011;76:1804–1810. doi: 10.1212/WNL.0b013e31821ccd3c
60. Сарра S.F., Perani D., Messa C., Miozzo A., Fazio F. Varieties of progressive non-fluent aphasia. Ann. N. Y. Acad. Sci. 1996;777:243–284.
61. Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol. 2012;11(6):545–555. doi: 10.1016/ S1474-4422(12)70099-6
62. Ogar J.M., Willock S., Baldo J., Wilkins D., Ludy C., Dronkers N. Clinical and anatomical correlates of apraxia of speech. Brain Lang. 2006;97:343–350. doi: 10.1016/j.bandl.2006.01.008
63. Ogar J.M., Dronkers N.F., Brambati S.M., Miller B.L., Gorno-Tempini M.L. Progressive nonfluent aphasia and its characteristic motor speech deficits. Alzheimer Dis. Assoc. Disord. 2007;21:S23–30. doi: 10.1097/WAD.0b013e31815d19fe
64. Josephs K.A., Duffy J.R., Strand E.A., Whitwell J.L., Layton K.F., Parisi J.E., Hauser M.E., Witte R.J., Boeve B.F., Knopman D.S., Dickson D.W., Jack C.R.Jr., Petersen R.C. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129:1385–1398. doi: 10.1093/brain/awl078
65. Benson D.F., Ardila A. Aphasia: A сlinical perspective. Oxford, England: Oxford University Press; 1996.
66. Hillis A.E., Oh S., Ken L. Deterioration of naming nouns versus verbs in primary progressive aphasia. Ann. Neurol. 2004;55:268–275. doi: 10.1002/ana.10812
67. Gorno-Tempini M.L., Ogar J.M., Brambati S.M., Wang P., Jeong J.H., Rankin K.P., Dronkers N.P., Miller B.L. Anatomical correlates of early mutism in progressive nonfluent aphasia. Neurology. 2006;67:1849– 1851. doi: 10.1212/01.wnl.0000237038.55627.5b
68. Gorno-Tempini M.L., Brambati S.M., Ginex V., Ogar J., Dronkers N.F., Marcone A., Perani D., Garibotto V., Cappa S.F., Miller B.L. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008;71(16);1227–1234. doi: 10.1212/01.wnl.0000320506.79811.da
69. Bjeddeli A. Rabochaja pamjat’ // Psihologija pamjati / Pod red. Ju.B. Gippenrejter, V.Ja. Romanova. 3-e izd. M.: Astrel’, 2008. (In Russ.).
70. Charles D., Olm C., Powers J., Ash S., Irwin D.J., McMillan C.T., Rascovsky K., Grossman M. Grammatical comprehension deficits in non-fluent/agrammatic primary progressive aphasia. Neurol. Neurosurg. Psychiatry. 2014;85(3):249–256. doi: 10.1136/jnnp-2013- 305749
71. Kohn S.E. Conduction Aphasia. Hillsdale: Lawrance Erlbaum Associates; 1992.
72. Sapolsky D., Bakkour A., Negreira A., Nalipinski P., Weintraub S., Mesulam M.M., Caplan D., Dickerson B.C. Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia. Neurology. 2010;75(4):358–366. doi: 10.1212/WNL.0b013e3181e-a15e8
73. Josephs K.A., Duffy J.R., Fossett T.R., Strand E.A., Claassen D.O., Whitwell J.L., Peller P.J. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. Arch. Neurol. 2010;67(5):596–605. doi: 10.1001/archneurol.2010.78
74. Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., O’Neil J.P., Lal R.A., Dronkers N.F., Miller B.L., Gorno-Tempini M.L. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388–401. doi: 10.1002/ana.21451
75. Mesulam M., Wicklund A., Johnson N., Rogalski E., Léger G.C., Rademaker A., Weintraub S., Bigio E.H. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann. Neurol. 2008;63(6):709–719. doi: 10.1002/ana.21388
76. Teichmann M., Kas A., Boutet C., Ferrieux S., Nogues M., Samri D., Rogan C., Dormont D., Dubois B., Migliaccio R. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain. 2013;136(Pt II):3474–3488. doi: 10.1093/ brain/awt266
77. Sajjadi S.A., Patterson K., Arnold R.J., Watson P.C., Nestor P.J. Primary progressive aphasia: a tale of two syndromes and the rest. Neurology. 2012;78(21):1670–1677. doi: 10.1212/WNL.0b013e3182574f79
78. Rohrer J.D., Rossor M.N., Warren J.D. Alzheimer’s pathology in primary progressive aphasia. Neurobiol. Aging. 2012;33(4):744–752. doi: 10.1016/j.neurobiolaging.2010.05.020
79. Hodges’ Frontotemporal Dementia. 2nd ed. / Ed. C. Bradford. Dick- erson Cambridge. University press. 2016.
80. Mezhdunarodnaja klassifikacija boleznej (10-j peresmotr) — MKB- 10: Klassifikacija psihicheskih i povedencheskih rasstrojstv. Klinicheskie opisanija i ukazanija po diagnostike / Per. na rus. jaz. pod red. Ju.L. Nullera, S.Ju. Cirkina. VOZ, Rossija, SPb., 1994. (In Russ.).
81. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, American Psychiatric Association, 2013.
82. WHO. Dementia fact sheet. March, 2015. http://www.who.int/me-diacentre/factsheets/fs362/en/ (accessed Nov 10, 2014).
83. Vieira R.T., Caixeta L,, Machado S., Silva A.C,, Nardi A.E., Arias-Carrión O., Carta M.G. Epidemiology of early-onset dementia: a review of the literature. Clin. Pract. Epidemiol. Ment. Health. 2013;9:88–95. doi: 10.2174/1745017901309010088
84. Ratnavalli E., Brayne C., Dawson K., Hodges J.R. The prevalence of fronto-temporal dementia. Neurology. 2002;58(11):1615–1621.
85. Knopman D.S., Roberts R.O. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J. Mol. Neurosci. 2011;45(3):330–335. doi: 10.1007/s12031-011-9538-y
86. Lambert M.A., Bickel H., Prince M., Fratiglioni L., Von Strauss E., Frydecka D., Kiejna A., Georges J., Reynish E.L. Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur. J. Neurol. 2014;21(4):563–569. doi: 10.1111/ene.12325
87. Hodges J.R., Davies R., Xuereb J., Kril J., Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61:349–354.
88. Bang J., Spina S., Miller B.L. Frontotemporal dementia. Lancet. 2015; 386:1672–1682. doi: 10.1016/S0140-6736(15)00461-4
89. Mihajlova N.M., Gavrilova S.I. Al’cgejmerovskij centr — innovacionnaja model’ ambulatornoj pomoshhi pozhilym bol’nym s kognitivnymi rasstrojstvami i demenciej. Psihiatrija. 2016;(3):42–51. (In Russ.).
90. Le Ber I. Genetics of frontotemporal lobar degeneration: an update and diagnosis algorithm. Rev. Neurol. 2013;169:811–819. doi: 10.1016/j.neurol.2013.07.014
91. Rohrer J.D., Guerreiro R., Vandrovcova J., Uphill J., Reiman D., Beck J., Isaacs A.M., Authier A., Ferrari R., Fox N.C., Mackenzie I.R., Warren J.D., de Silva R., Holton J., Revesz T., Hardy J., Mead S., Rossor M.N. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451–1456. doi: 10.1212/ WNL.0b013e3181bf997a
92. Le Ber I. Genetics of frontotemporal lobar degeneration: an update and diagnosis algorithm. Rev. Neurol. 2013;169:811–819. doi: 10.1016/j.neurol.2013.07.014
93. Goldman J.S., Rademakers R., Huey E.D., Boxer A.L., Mayeux R., Miller B.L., Boeve B.F. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology. 2011;76:475–483. doi: 10.1212/WNL.0b013e31820a0d13
94. Rademakers R., Neumann M., Mackenzie I.R. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 2012;8(8):423–434. doi: 10.1038/nrneurol.2012.117
95. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998; 393(6686):702–705. doi: 10.1038/31508
96. Gijselinck I., Van Broeckhoven C., Cruts M. Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum. Mutat. 2008;29(12):1373–1386. doi: 10.1002/humu.20785
97. Shankaran S.S., Capell A., Hruscha A.T., Fellerer K., Neumann M., Schmid B., Haass C. Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J. Biol. Chem. 2008;18;283(3):1744–1753. doi: 10.1074/jbc. M705115200
98. Toh H., Chitramuthu B.P., Bennett H.P., Bateman A. Structure, function, and mechanism of progranulin; the brain and beyond. J. Mol. Neurosci. 2011;45(3):538–548. doi: 10.1007/s12031-011-9569-4
99. Tang W., Lu Y., Tian Q.Y., Zhang Y., Guo F.J., Liu G.Y., Syed N.M., Lai Y., Lin E.A., Kong L., Su J., Yin F., Ding A.H., Zanin-Zhorov A., Dustin M.L., Tao J., Craft J., Yin Z., Feng J.Q., Abramson S.B., Yu X.P., Liu C.J. The growth factor progranulin binds to TNF receptors and is therapeutic against infl ammatory arthritis in mice. Science. 2011; 332(6028):478–484. doi: 10.1126/science.1199214
100. Miller Z.A., Rankin K.P., Graff-Radford N.R., Takada L.T., Sturm V.E., Cleveland C.M., Criswell L.A., Jaeger P.A., Stan T., Heggeli K.A., Hsu S.C., Karydas A., Khan B.K., Grinberg L.T., Gorno-Tempini M.L., Boxer A.L., Rosen H.J., Kramer J.H., Coppola G., Geschwind D.H., Rademakers R., Seeley W.W., Wyss-Coray T., Miller B.L. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J. Neurol. Neurosurg. Psychiatry. 2013;84(9):956–962. doi: 10.1136/ jnnp-2012-304644
101. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R. Expanded GGGG- CC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256. doi: 10.1016/j.neuron.2011.09.011
102. Renton A.E., Majounie E., Waite A., Simón-Sánchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Hölttä-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chiò A., Restagno G., Borghero G., Sabatelli M.; ITALSGEN Consortium, Heckerman D., Rogaeva E., Zinman L., Rothstein J.D., Sendtner M., Drepper C., Eichler E.E., Alkan C., Abdullaev Z., Pack S.D., Dutra A., Pak E., Hardy J., Singleton A., Williams N.M., Heutink P., Pickering-Brown S., Morris H.R., Tienari P.J., Traynor B.J. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21- linked ALS-FTD. Neuron. 2011.Oct 20;72(2):257–268. doi: 10.1016/j. neuron.2011.09.010
103. Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 2013;34(6):812–826. doi: 10.1002/humu.22319
104. Duncan J.E., Goldstein L.S. The genetics of axonal transport and axonal transport disorders. PLoS Genet. 2006.Sep 29;2(9):e124. PLoS Genetic, PMID 17009871 doi: 10.1371/journal.pgen.0020124
105. Golimstok A., Cámpora N., Rojas J.I., Fernandez M.C., Elizondo C., Soriano E., Cristiano E. Cardiovascular risk factors and frontotemporal dementia: a case-control study. Transl. Neuro. 2014;3:13. doi: 10.1186/2047-9158-3-13
106. Borroni B., Alberici A., Agosti C., Premi E., Padovani A. Education plays a different role in frontotemporal dementia and Alzheimer’s disease. Int. J. Ger. Psychiatry. 2008;23(8):796–80026. doi: 10.1002/ gps.1974
107. Nyberg J., Åberg M.A., Schiöler L., Nilsson M., Wallin A., Torén K., Kuhn H.G. Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. Brain. 2014;137(Pt 5):1514–1523. doi: 10.1093/ brain/awu041
108. Barbier M., Camuzat A., Houot M., Clot F., Caroppo P., Clémence F., Rinaldi D., Pasquier F., Hannequin D., Pariente J., Larcher K., Brice A., Génin E., Sabbagh A., Le Ber I. Factors influencing the age at onset in familial frontotemporal lobar dementia Important weight of genetics. Neurol. Genet. 2017;3:e203. doi: 10.1212/ NXG.0000000000000203
109. Boxer A.L., Boeve B.F. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis. Assoc. Disord. 2007;21(4):S79–87. doi: 10.1097/WAD.0b013e31815c345e
110. Nardell M., Tampi R.R. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am. J. Alzheimers Dis. Other Demen. 2014;29(2):123–132. doi: 10.1177/1533317513507375
111. López-Pousa S., Calvó-Perxas L., Lejarreta S., Cullell M., Meléndez R., Hernández E., Bisbe J., Perkal H., Manzano A., Roig A.M., Turró-Garriga O., Vilalta-Franch J., Garre-Olmo J.; Registry of Dementias of Girona Study Group (ReDeGi Study Group). Use of antidementia drugs in frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen. 2012;27(4):260–266. doi: 10.1177/1533317512447887
112. Huey E.D., Putnam K.T., Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17–22. doi: 10.1212/01. wnl.0000191304.55196.4d
113. Swartz J.R., Miller B.L., Lesser I.M., Darby A,L. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J. Clin. Psychiatry. 1997;58(5):212–216.
114. Mendez M.F. Frontotemporal dementia: therapeutic interventions. Front. Neurol. Neurosci. 2009;24:168–178. doi: 10.1159/000197896
115. Fellgiebel A., Müller M.J., Hiemke C., Bartenstein P., Schreckenberg- er M. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J. Biol. Psychiatry. 2007;8(2):123–126. doi: 10.1080/15622970601016538
116. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am. J. Alzheimers Dis. Other Demen. 2003;18(4):205–214. doi: 10.1177/153331750301800410
117. Mendez M.F., Shapira J.S., McMurtray A., Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatry. 2007;15(1):84–87. doi: 10.1097/01.JGP.0000231744.69631.33
118. Kertesz A., Morlog D., Light M., Blair M., Davidson W., Jesso S., Brashear R. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord. 2008;25(2):178– 185. doi: 10.1159/000113034
119. O’Brien J.T., Burns A.; BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J. Psychopharmacol. 2011;25(8):997–1019. doi: 10.1177/0269881110387547
120. Mecocci P., Bladstrom A., Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int. J. Geriatr. Psychiatry. 2009;24(5):532–538. doi: 10.1002/ gps.2226
121. Ferris S., Ihl R., Robert P., Winblad B., Gatz G., Tennigkeit F., Gauthier S. Treatment effects of Memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement. 2009;5(5):369–374. doi: 10.1016/j.jalz.2009.05.604
122. Grossberg G.T., Pejović V., Miller M.L., Graham S.M. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009;27(2):164–172. doi: 10.1159/000200013
123. Swanberg M.M. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis. Assoc. Disord. 2007;21(2):164–166. doi: 10.1097/WAD.0b013e318047df5d
124. Boxer A.L., Knopman D.S., Kaufer D.I., Grossman M., Onyike C., Graf-Radford N., Mendez M., Kerwin D., Lerner A., Wu C.K., Koestler M., Shapira J., Sullivan K., Klepac K., Lipowski K., Ullah J., Fields S., Kramer J.H., Merrilees J., Neuhaus J., Mesulam M.M., Miller B.L. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149–156. doi: 10.1016/ S1474-4422(12)70320-4
125. Chow T.W., Fam D., Graff-Guerrero A., Verhoeff N.P., Tang-Wai D.F., Masellis M., Black S.E., Wilson A.A., Houle S., Pollock B.G. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. Int. J. Geriatr. Psychiatry. 2013;28(3):319–325. doi: 10.1002/gps.3832. Epub 2012 Jun 4
126. Kishi T., Matsunaga S., Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr. Dis. Treat. 2015 12;11:2883-5. doi: 10.2147/NDT.S94430
127. Ikeda M., Shigenobu K., Fukuhara R., Hokoishi K., Maki N., Nebu A., Komori K., Tanabe H. Efficacy of fluvoxamine as a treatment for behavioral symptoms in FTLD patients. Dement. Geriatr. Cogn. Disord. 2004;17:117–121. doi: 10.1159/000076343
128. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314.
129. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State. A practical method of grading the cognitive state of patients for the clinician. Journal of Psychiatry Research. 1975;12(3):189–198.
130. Lebert F., Stekke W., Hasenbroekx C., Pasquier F. Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord. 2004;17:335–359. doi: 10.1159/000077171
131. Moretti R., Torre P., Antonello R.M., Cazzato G., Bava A. Frontotemporal dementia: Paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur. Neurol. 2003;18(4):205–214. doi: 10.1159/000067021
132. Deakin J.B., Rahman S., Nestor P.J., Hodges J.R., Sahakian B.J. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004;172(4):400–408. doi: 10.1007/ s00213-003-1686-5
133. Fellgiebel A., Müller M.J., Hiemke C., Bartenstein P., Schreckenberger M. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J. Biol. Psychiatry. 2007;8(2):123–126. doi: 10.1080/15622970601016538
134. Pijnenburg Y.A., Sampson E.L., Harvey R.J., Fox N.C., Rossor M.N. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int. J. Geriatr. Psychiatry. 2003;18(1):67–72. doi: 10.1002/gps.774
135. Jesso S., Morlog D., Ross S., Pell M.D., Pasternak S.H., Mitchell D.G., Kertesz A., Finger E.C. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011;134(Pt 9):2493– 2501. doi: 10.1093/brain/awr171
136. Dolder C.R., Davis L.N., McKinsey J. Use of psychostimulants in patients with dementia. Pharmacother. 2010;44(10):1624–1632. doi: 10.1345/aph.1P341
137. Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42–52. doi: 10.1016/j.neuron.2009.03.024
138. Sanders D.W., Kaufman S.K., DeVos S.L., Sharma A.M., Mirbaha H., Li A., Barker S.J., Foley A.C., Thorpe J.R., Serpell L.C., Miller T.M., Grinberg L.T., Seeley W.W., Diamond M.I. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271–1288. doi: 10.1016/j.neuron.2014.04.047
139. Yanamandra K., Kfoury N., Jiang H., Mahan T.E., Ma S., Maloney S.E., Wozniak D.F., Diamond M.I., Holtzman D.M. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–414. doi: 10.1016/j.neuron.2013.07.046
140. Wischik C.M., Harrington C.R., Storey J.M. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 2014;88(4):529–539. doi: 10.1016/j.bcp.2013.12.008
141. Chan J.H., Lim S., Wong W.S. Antisense oligonucleotide: from design to therapeutic application. Clinical and Experimental Pharmacology and Physiology. 2006;33(5–6):533–540. doi: 10.1111/j.1440-1681.2006.04403.x
142. Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.R., Jiang J., Watt A.T., Chun S., Katz M., Qiu J., Sun Y., Ling S.C., Zhu Q., Polymenidou M., Drenner K., Artates J.W., McAlonis-Downes M., Markmiller S., Hutt K.R., Pizzo D.P., Cady J., Harms M.B., Baloh R.H., Vandenberg S.R., Yeo G.W., Fu X.D., Bennett C.F., Cleveland D.W., Ravits J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530–45339. doi: 10.1073/pnas.1318835110
143. DeVos S.L., Goncharoff D.K., Chen G., Kebodeaux C.S., Yamada K., Stewart F.R., Schuler D.R., Maloney S.E., Wozniak D.F., Rigo F., Bennett C.F., Cirrito J.R., Holtzman D.M., Miller T.M. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 2013;33(31):12887–12897. doi: 10.1523/JNEUROSCI.2107-13.2013
144. Cenik B., Sephton C.F., Dewey C.M., Xian X., Wei S., Yu K., Niu W., Coppola G., Coughlin S.E., Lee S.E., Dries D.R., Almeida S., Geschwind D.H., Gao F.B., Miller B.L., Farese R.V. Jr, Posner B.A., Yu G., Herz J. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 2011;286(18):16101–16108. doi: 10.1074/jbc.M110.193433
145. Capell A., Liebscher S., Fellerer K., Brouwers N., Willem M., Lammich S., Gijselinck I., Bittner T., Carlson A.M., Sasse F., Kunze B., Steinmetz H., Jansen R., Dormann D., Sleegers K., Cruts M., Herms J., Van Broeckhoven C., Haass C. Rescue of progranulin defi ciency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J. Neuro. 2011;31(5):1885–1894. doi: 10.1523/JNEUROSCI.5757-10.2011
146. Bang J., Spina S., Miller B.L. Frontotemporal dementia. Lancet. 2015;386(10004):1672–1682. doi: 10.1016/S0140-6736(15)00461-4
147. Roberson E.D., Hesse J.H., Rose K.D., Slama H., Johnson J.K., Yaffe K., Forman M.S., Miller C.A., Trojanowski J.Q., Kramer J.H., Miller B.L. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology. 2005;65(5):719–725. doi: 10.1212/01. wnl.0000173837.82820.9f
148. Rascovsky K., Salmon D.P., Lipton A.M., Leverenz J.B., DeCarli C., Jagust W.J., Clark C.M., Mendez M.F., Tang-Wai D.F., Graff-Radford N.R., Galasko D. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. 2005;65(3):397–403. doi: 10.1212/01.wnl.0000171343.43314.6e
149. Riedl L., Mackenzie I.R., Förstl H., Kurz A., Diehl-Schmid J. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr. Dis. Treat. 2014;10:297–310.
150. Chiu W.Z., Kaat L.D., Seelaar H., Rosso S.M., Boon A.J., Kamphorst W., van Swieten J.C. Survival in progressive supranuclear palsy and frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 2010; 81(4):441–445. doi: 10.1136/jnnp.2009.195719
151. Nunnemann S., Last D., Schuster T., Förstl H., Kurz A., Diehl-Schmid J. Survival in a German population with frontotemporal lobar degeneration. Neuroepidemiology. 2011;37(3–4):160–165. doi: 10.1159/000331485
152. Hodges J.R., Davies R., Xuereb J., Kril J., Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61(3):349–354.
153. Xie S.X., Forman M.S., Farmer J., Moore P., Wang Y., Wang X., Clark C.M., Coslett H.B., Chatterjee A., Arnold S.E., Rosen H., Karlawish J.H., Van Deerlin V.M., Lee V.M., Trojanowski J.Q., Grossman M. Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry. 2008;79(2):126–129. doi: 10.1136/jnnp.2006.110288.
Review
For citations:
Fedorova Ya. Frontotemporal dementia. Psychiatry (Moscow) (Psikhiatriya). 2018;1(77):60-85. (In Russ.) https://doi.org/2618-6667-2018-77-60-85
Views:
1311
Email this article 
